Wei Lin - Feb 1, 2022 Form 4 Insider Report for Erasca, Inc. (ERAS)

Role
Chief Medical Officer
Signature
/s/ Ebun S. Garner, Attorney-in-Fact
Stock symbol
ERAS
Transactions as of
Feb 1, 2022
Transactions value $
$18,123
Form type
4
Date filed
2/3/2022, 06:54 PM
Previous filing
Jul 15, 2021
Next filing
Feb 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ERAS Common Stock Other $18.1K +1.56K +0.5% $11.60 314K Feb 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERAS Stock Option (Right to Buy) Award $0 +272K $0.00 272K Feb 1, 2022 Common Stock 272K $11.54 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,562 shares acquired under the Erasca, Inc. employee stock purchase plan on December 15, 2021.
F2 1/48th of the shares subject to the option vest monthly following February 2, 2022, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.